Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
Background Idiopathic pulmonary fibrosis (IPF) is characterised by constant threat of acute exacerbation of IPF (AE-IPF). It would be significant to identify risk factors of AE-IPF. We sought to determine the prognostic value of lung transplantation candidacy testing for AE-IPF and describe explant...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2020-10-01
|
Series: | ERJ Open Research |
Online Access: | http://openres.ersjournals.com/content/6/4/00261-2019.full |
id |
doaj-09dae59b1ea746e8b7c655c9780464b2 |
---|---|
record_format |
Article |
spelling |
doaj-09dae59b1ea746e8b7c655c9780464b22021-01-18T17:10:09ZengEuropean Respiratory SocietyERJ Open Research2312-05412020-10-016410.1183/23120541.00261-201900261-2019Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosisYaniv Dotan0William B. Shapiro1Eneida Male2Eduardo C. Dominguez3Amandeep Aneja4Zhao Huaqing5Chandra Dass6Kartik Shenoy7Nathaniel Marchetti8Francis C. Cordova9Gerard J. Criner10A. James Mamary11 Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Clinical Science, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Clinical Radiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Background Idiopathic pulmonary fibrosis (IPF) is characterised by constant threat of acute exacerbation of IPF (AE-IPF). It would be significant to identify risk factors of AE-IPF. We sought to determine the prognostic value of lung transplantation candidacy testing for AE-IPF and describe explant pathology of recipients with and without AE-IPF before lung transplantation. Methods Retrospective cohort study of 89 IPF patients listed for lung transplantation. Data included pulmonary function testing, echocardiography, right heart catheterisation, imaging, oesophageal pH/manometry and blood tests. Explanted tissue was evaluated by pulmonary pathologists and correlated to computed tomography (CT) findings. Results Out of 89 patients with IPF, 52 were transplanted during stable IPF and 37 had AE-IPF before transplantation (n=28) or death (n=9). There were no substantial differences in candidacy testing with and without AE-IPF. AE-IPF had higher rate of decline of forced vital capacity (FVC) (21±22% versus 4.8±14%, p=0.00019). FVC decline of >15% had a hazard ratio of 7.2 for developing AE-IPF compared to FVC decline of <5% (p=0.004). AE-IPF had more secondary diverse histopathology (82% versus 29%, p<0.0001) beyond diffuse alveolar damage. There was no correlation between ground-glass opacities (GGO) on chest CT at any point to development of AE-IPF (p=0.077), but GGO during AE-IPF predicted secondary pathological process beyond diffuse alveolar damage. Conclusions Lung transplantation candidacy testing including reflux studies did not predict AE-IPF besides FVC absolute decline. CT did not predict clinical or pathological AE-IPF. Secondary diverse lung pathology beyond diffuse alveolar damage was present in most AE-IPF, but not in stable IPF.http://openres.ersjournals.com/content/6/4/00261-2019.full |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yaniv Dotan William B. Shapiro Eneida Male Eduardo C. Dominguez Amandeep Aneja Zhao Huaqing Chandra Dass Kartik Shenoy Nathaniel Marchetti Francis C. Cordova Gerard J. Criner A. James Mamary |
spellingShingle |
Yaniv Dotan William B. Shapiro Eneida Male Eduardo C. Dominguez Amandeep Aneja Zhao Huaqing Chandra Dass Kartik Shenoy Nathaniel Marchetti Francis C. Cordova Gerard J. Criner A. James Mamary Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis ERJ Open Research |
author_facet |
Yaniv Dotan William B. Shapiro Eneida Male Eduardo C. Dominguez Amandeep Aneja Zhao Huaqing Chandra Dass Kartik Shenoy Nathaniel Marchetti Francis C. Cordova Gerard J. Criner A. James Mamary |
author_sort |
Yaniv Dotan |
title |
Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis |
title_short |
Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis |
title_full |
Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis |
title_fullStr |
Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis |
title_full_unstemmed |
Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis |
title_sort |
clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis |
publisher |
European Respiratory Society |
series |
ERJ Open Research |
issn |
2312-0541 |
publishDate |
2020-10-01 |
description |
Background
Idiopathic pulmonary fibrosis (IPF) is characterised by constant threat of acute exacerbation of IPF (AE-IPF). It would be significant to identify risk factors of AE-IPF. We sought to determine the prognostic value of lung transplantation candidacy testing for AE-IPF and describe explant pathology of recipients with and without AE-IPF before lung transplantation.
Methods
Retrospective cohort study of 89 IPF patients listed for lung transplantation. Data included pulmonary function testing, echocardiography, right heart catheterisation, imaging, oesophageal pH/manometry and blood tests. Explanted tissue was evaluated by pulmonary pathologists and correlated to computed tomography (CT) findings.
Results
Out of 89 patients with IPF, 52 were transplanted during stable IPF and 37 had AE-IPF before transplantation (n=28) or death (n=9). There were no substantial differences in candidacy testing with and without AE-IPF. AE-IPF had higher rate of decline of forced vital capacity (FVC) (21±22% versus 4.8±14%, p=0.00019). FVC decline of >15% had a hazard ratio of 7.2 for developing AE-IPF compared to FVC decline of <5% (p=0.004). AE-IPF had more secondary diverse histopathology (82% versus 29%, p<0.0001) beyond diffuse alveolar damage. There was no correlation between ground-glass opacities (GGO) on chest CT at any point to development of AE-IPF (p=0.077), but GGO during AE-IPF predicted secondary pathological process beyond diffuse alveolar damage.
Conclusions
Lung transplantation candidacy testing including reflux studies did not predict AE-IPF besides FVC absolute decline. CT did not predict clinical or pathological AE-IPF. Secondary diverse lung pathology beyond diffuse alveolar damage was present in most AE-IPF, but not in stable IPF. |
url |
http://openres.ersjournals.com/content/6/4/00261-2019.full |
work_keys_str_mv |
AT yanivdotan clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT williambshapiro clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT eneidamale clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT eduardocdominguez clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT amandeepaneja clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT zhaohuaqing clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT chandradass clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT kartikshenoy clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT nathanielmarchetti clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT francisccordova clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT gerardjcriner clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis AT ajamesmamary clinicalpredictorsandexplantlungpathologyofacuteexacerbationofidiopathicpulmonaryfibrosis |
_version_ |
1724333042319753216 |